The positron emission tomography (PET) radioligand α-[C]methyl-l-tryptophan ([C]AMT) has been used to assess tryptophan metabolism in cancer, epilepsy, migraine, and autism. Despite its extensive application, the utility of this tracer is currently hampered by the short half-life of the radionuclide used for its labeling (C, = 20.4 min). We herein report the design, synthesis, radiolabeling, and initial evaluation of a fluorine-18 (F, = 109.7 min) labeled analogue that is fluorinated in the 6-position of the aromatic ring ([F]6-F-AMTr). In a head-to-head comparison between [F]6-F-AMTr and [C]AMT in mice using PET, peak brain radioactivity, regional brain distribution, and kinetic profiles were similar between the two tracers. [F]6-F-AMTr was however not a substrate for IDO1 or TPH as determined in enzymatic assays. The brain uptake of the tracer is thus more likely related to LAT1 transport over the blood-brain barrier than metabolism along the serotonin or kynurenine pathways.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acschemneuro.0c00135 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!